Filing Analysis
💸 Securities Offering
Filed Jun 11, 2026
🟠 HIGH
VSee Health, Inc. entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. on June 2, 2026, providing the company access to up to $10 million in equity financing through 2029.
🚩 Red Flags
- The SEPA is a 'death spiral' style financing mechanism where shares are issued at a discount (97% of VWAP), which typically leads to significant dilution and downward pressure on the stock price.
- The company is an 'Emerging Growth Company', which often correlates with higher volatility and less stringent reporting requirements.
📋 Key Facts
- Commitment Amount: Up to $10 million in Common Stock purchases by YA II PN, LTD.
- Pricing: Shares will be issued at 97% of the lowest daily VWAP during a 3-day pricing period.
- Fees: $25,000 structuring fee and 532,481 commitment shares (approx. 1% of commitment amount).
- Exchange Cap: Maximum issuance of 9,715,140 shares (approx. 19.99% of outstanding shares) without stockholder approval.
- Ownership Limit: Investor cannot exceed 4.99% beneficial ownership of outstanding shares.
- Duration: Agreement expires June 2, 2029, or upon full utilization of the $10 million.
💸 Securities Offering
Filed Jun 11, 2026
🟠 HIGH
VSee Health entered into a Securities Purchase Agreement on June 8, 2026, issuing a secured promissory note to an institutional investor (ADI Funding LLC) for a principal amount of $271,739.13.
🚩 Red Flags
- Extremely high interest rate (18% per annum) suggests high risk or desperation for liquidity
- The loan is secured by company assets, increasing the risk of asset seizure upon default
- The presence of an Original Issue Discount (OID) is often a sign of predatory or high-cost short-term financing
- Multiple 8-K items (1.01, 2.03, 3.02) in a single filing
📋 Key Facts
- Principal amount of Promissory Note: $271,739.13
- Includes an original issue discount (OID) of $21,739.13
- Interest rate: 18% per annum
- Maturity date: December 8, 2026
- Prepayment fee: 10% of the amount being prepaid
- The note is secured by certain assets of the company via a Security Agreement
- Repayment is mandatory within two business days of receiving proceeds from an equity line of credit financing arrangement with the same holder
🤝 Related Party Transaction
Filed Jun 05, 2026
🟠 HIGH
VSee Health entered into a Stock Purchase Agreement with its co-CEO and Chairman, Milton Chen, to sell all equity of its wholly-owned subsidiary, VSee Lab, to him. In exchange, Mr. Chen transferred 2,870,069 shares of VSee Health common stock back to the company and resigned from his executive and board positions.
🚩 Red Flags
- Related-party transaction: The asset sale and stock transfer involved the company's own co-CEO and Chairman.
- Multiple 8-K items in a single filing (1.01, 2.01, 3.02, 5.02).
- Significant divestiture of a wholly-owned subsidiary (VSee Lab) to an insider.
- Sudden resignation of the Chairman and co-CEO.
📋 Key Facts
- Transaction Date: May 31, 2026
- Asset Disposition: Company sold all equity securities of VSee Lab, Inc. (a wholly-owned subsidiary) to Milton Chen.
- Consideration: Mr. Chen transferred 2,870,069 shares of VSee Health common stock to the Company.
- Management Change: Milton Chen resigned as co-CEO and Chairman of the Board effective May 31, 2026.
- New Leadership: Dr. Imoigele Aisiku appointed as sole CEO and Chairman of the Board.
- Liability Split: Mr. Chen is responsible for VSee Lab indebtedness not paid at closing, while the Company retains liabilities occurring prior to the closing date (excluding certain sales/use taxes).
💸 Securities Offering
Filed Mar 03, 2026
🟡 MEDIUM
VSee Health, Inc. stockholders approved a private placement proposal at a special meeting held on March 2, 2026. The approval allows for the issuance of up to 19,672,130 shares of common stock to certain warrant holders, satisfying Nasdaq Listing Rule 5635(d).
🚩 Red Flags
- Significant potential dilution: The approved issuance of 19,672,130 shares represents approximately 45.5% of the 43,244,355 shares outstanding as of the record date.
📋 Key Facts
- Special Meeting of stockholders held on March 2, 2026.
- As of the February 2, 2026 record date, there were 43,244,355 shares of common stock outstanding.
- Stockholders approved the issuance of up to 19,672,130 shares of common stock to warrant holders.
- The Private Placement Proposal passed with 14,109,726 votes FOR and 7,698,963 votes AGAINST.
- The Adjournment Proposal was withdrawn as the primary proposal was successfully adopted.
📝 Material Agreement
Filed Feb 19, 2026
🟡 MEDIUM
VSee Health disclosed two interrelated agreements with GoMyRx, Inc., a digital prescription fulfillment platform: a Managed Services Agreement (MSA) for cost-plus-10% services dated December 26, 2025, and a Stock Purchase Agreement dated January 16, 2026, under which VSEE will acquire 10% of GMRx for $2.0 million from Go Biz Holdings, LLC. The filing was made approximately 55 days after the earliest reported event, well beyond the standard 4-business-day 8-K deadline.
🚩 Red Flags
- Significantly late filing: earliest event December 26, 2025 but 8-K not filed until February 19, 2026 (~55 days), far exceeding the 4-business-day requirement
- $2.0 million equity investment in a private company with no disclosed financials for GMRx — shareholders cannot assess whether the implied $20M valuation is reasonable
- Secondary share purchase from Go Biz Holdings means the $2M capital goes to the selling entity, not to GMRx for growth — raises questions about who benefits
- Intertwined service and equity relationship: VSEE is simultaneously a service provider to and equity investor in GMRx, creating potential conflicts of interest
- GMRx can terminate the MSA with only 20 days notice, an asymmetrically unfavorable term for VSEE
- Restricted shares with no clear liquidity path — VSEE's $2M investment is effectively locked up in a private, illiquid position
- No disclosure of any relationship between Go Biz Holdings and VSEE insiders or directors — the filing is silent on whether this is a related-party transaction
📋 Key Facts
- VSEE entered a Managed Services Agreement with GoMyRx, Inc. on December 26, 2025, to provide platform administration, customer/user support, vendor coordination, and reporting/governance services
- MSA billing is at actual cost plus 10% margin, invoiced monthly — a modest markup
- MSA expires December 26, 2027 with optional 6-month extensions; GMRx can terminate with only 20 days written notice
- On January 16, 2026, VSEE agreed to purchase $2.0 million of GMRx common stock from Go Biz Holdings, LLC, representing 10% ownership in GMRx (implying a $20M valuation for GMRx)
- Shares purchased are restricted securities under Section 4(a)(2) / Rule 506 of Regulation D — cannot be freely sold
- GoMyRx is described as 'an affiliate company of the GoMyDocs healthcare ecosystem'
- The $2M purchase is a secondary transaction (from Go Biz Holdings), meaning proceeds go to the seller, not to GMRx for business operations
- Filing signed by Co-CEO Imoigele Aisiku on February 19, 2026 — 55 days after the December 26 MSA event
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.